Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized placebo controlled pilot microCT study to estimate the effect of treatment with denosumab (AMG 162) and alendronate sodium in postmenopausal women with low bone mineral density.

Next Previous
Trial Profile

A multicenter, randomized placebo controlled pilot microCT study to estimate the effect of treatment with denosumab (AMG 162) and alendronate sodium in postmenopausal women with low bone mineral density.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denosumab (Primary) ; Alendronic acid
  • Indications Bone resorption; Fracture; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Amgen

    • Most Recent Events

    • 02 Apr 2014 Results comparing trabecular bone score and bone mineral density presented at the 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 08 Oct 2013 Results assessing bone measures at the lumbar spine, including the trabecular bone score, presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
    • 16 Oct 2012 Results assessing effects of treatment on trabecular bone volume fraction and intracortical porosity presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top